Inovio Pharmaceuticals Inc INO

Inovio Pharmaceuticals Inc is a biotechnology company founded in June 1983 by David B. Weiner. Headquartered in Plymouth Meeting, Pennsylvania, and serving a worldwide client-base, it specialises in the discovery, development and sales of cutting-edge DNA medicines for the treatment of severe and life-threatening illnesses. The high-risk Human Papilloma Virus (HPV), various cancers and infectious diseases are on its target list. Inovio is not only the first but the only biotech company to clinically demonstrate the effective delivery of DNA medicines directly into the body’s cells using its proprietary smart device.

In 2020, the company saw its stock price rocket by 343% through Q2, primarily driven by its high-velocity race through the early stages of developing a coronavirus vaccine (INO-4800). At the same time, it was involved in phase-3 clinical trials of a potential vaccine for HPV-related precancerous dysplasia. By June 2020, Inovio Pharmaceuticals Inc had successfully raised a total of $295m in funding over 11 rounds. Inovio Pharmaceuticals Inc.’s stock is traded on the NASDAQ index under the ticker ‘INO’.

For those who wish to buy stock in this company, it should be noted that the development of such complex, high-end medicines is often an exceptionally lengthy process taking many years. Success sufficient to achieve official approval can be elusive, but the rewards can be spectacular.

If you are considering whether to buy shares in Inovio Pharmaceuticals, add it to your watchlist using the ticker ‘INO’ on eToro.